As of 2026-03-12, the Relative Valuation of Arbutus Biopharma Corp (ABUS) is (5.10) USD. This relative valuation is based on P/E multiples. With the latest stock price at 4.70 USD, the upside of Arbutus Biopharma Corp based on Relative Valuation is -208.6%.
The range of the Relative Valuation is (4.79) - (5.17) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 21.3x - 26.2x | 23.8x |
| Forward P/E multiples | 21.8x - 23.5x | 22.6x |
| Fair Price | (4.79) - (5.17) | (5.10) |
| Upside | -202.1% - -210.0% | -208.6% |
| Date | P/E |
| 2026-03-11 | -21.36 |
| 2026-03-10 | -21.43 |
| 2026-03-09 | -21.47 |
| 2026-03-06 | -20.61 |
| 2026-03-05 | -21.38 |
| 2026-03-04 | -21.61 |
| 2026-03-03 | -21.34 |
| 2026-03-02 | -21.24 |
| 2026-02-27 | -21.20 |
| 2026-02-26 | -21.38 |
| 2026-02-25 | -20.93 |
| 2026-02-24 | -20.29 |
| 2026-02-23 | -19.97 |
| 2026-02-20 | -19.42 |
| 2026-02-19 | -19.29 |
| 2026-02-18 | -18.79 |
| 2026-02-17 | -18.97 |
| 2026-02-13 | -18.11 |
| 2026-02-12 | -18.24 |
| 2026-02-11 | -18.92 |
| 2026-02-10 | -18.92 |
| 2026-02-09 | -18.42 |
| 2026-02-06 | -17.47 |
| 2026-02-05 | -16.69 |
| 2026-02-04 | -17.65 |
| 2026-02-03 | -18.70 |
| 2026-02-02 | -19.97 |
| 2026-01-30 | -18.79 |
| 2026-01-29 | -18.79 |
| 2026-01-28 | -18.83 |
| 2026-01-27 | -18.92 |
| 2026-01-26 | -18.56 |
| 2026-01-23 | -18.47 |
| 2026-01-22 | -18.92 |
| 2026-01-21 | -18.83 |
| 2026-01-20 | -19.13 |
| 2026-01-16 | -18.47 |
| 2026-01-15 | -21.38 |
| 2026-01-14 | -21.74 |
| 2026-01-13 | -21.56 |
| 2026-01-12 | -20.47 |
| 2026-01-09 | -21.02 |
| 2026-01-08 | -21.15 |
| 2026-01-07 | -22.20 |
| 2026-01-06 | -21.79 |
| 2026-01-05 | -21.43 |
| 2026-01-02 | -21.70 |
| 2025-12-31 | -21.88 |
| 2025-12-30 | -21.02 |
| 2025-12-29 | -21.47 |